申请人:Boehringer Biochemia Robin S.p.A.
公开号:US05047414A1
公开(公告)日:1991-09-10
Compounds of formula I, and pharmaceutical compositions containing compounds of formula I ##STR1## wherein: R.sub.1 is: (a) COCH.sub.3, COC.sub.6 H.sub.5, CN or NO.sub.2 ; (b) COORa wherein Ra is hydrogen, or optionally substituted C.sub.1 -C.sub.6 straight or branched alkyl; R.sub.2 is optionally substituted phenyl; pentafluorophenyl; .alpha.- or .beta.-naphthyl; a five- or six-membered heterocyclic ring; .alpha.-benzo[2,3-b]-1,4-dioxan-.alpha.-yl; or .alpha.-benzofuroxanyl; R.sub.3 is COORa; P is hydrogen, --(CH.sub.2).sub.p --W, or C.sub.1 -C.sub.8 linear or branched alkyl; N--P.sub.1 is the residue of a primary or secondary amino group wherein P.sub.1 is hydrogen, C.sub.1 -C.sub.6 lower linear or branched alkyl group, or --(CH.sub.2).sub.p --W; and P, taken together with P.sub.1 and the nitrogen atom to which P.sub.1 is linked, may form a pyrrolidine or a piperidine ring; W is hydroxymethyl, formyloxymethyl, CO.sub.2 R wherein R is hydrogen or C.sub.1 -C.sub.4 lower alkyl, CN, saturated or unsaturated heterocyclic ring, C.sub.3 -C.sub.7 cycloalkyl ring, or optionally substituted phenyl; m is an integer from 1 to 3; n is zero or an integer from 1 to 2; p is zero or an integer from 1 to 3. The compounds of formula (I) and compositions containing them are effective in anti-hypertensive therapy.
公式I的化合物和含有公式I化合物的制药组合物,其中:
R.sub.1是:(a) COCH.sub.3,COC.sub.6 H.sub.5,CN或NO.sub.2; (b) COORa,其中Ra是氢,或可选取代的C.sub.1-C.sub.6直链或支链烷基; R.sub.2是可选取代的苯基; 五氟苯基; .alpha.-或.beta.-萘基; 五元或六元杂环环; .alpha.-苯并[2,3-b]-1,4-二氧杂环-.alpha.-基; 或.alpha.-苯并呋喃基; R.sub.3是COORa; P是氢,-(CH.sub.2).sub.p-W,或C.sub.1-C.sub.8线性或支链烷基; N-P.sub.1是一级或二级氨基残基,其中P.sub.1是氢,C.sub.1-C.sub.6较低的直链或支链烷基,或-(CH.sub.2).sub.p-W; P,与P.sub.1和P.sub.1连接的氮原子一起,可以形成吡咯烷或哌嗪环; W是羟甲基,甲酰氧甲基,CO.sub.2 R,其中R是氢或C.sub.1-C.sub.4较低烷基,CN,饱和或不饱和杂环环,C.sub.3-C.sub.7环烷基,或可选取代的苯基; m是1到3的整数; n为零或1到2的整数; p为零或1到3的整数。公式(I)的化合物和含有它们的组合物在降压疗法中有效。